IRIS

Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma / Ascierto, P.. - In: ASIA PACIFIC JOURNAL OF CLINICAL ONCOLOGY. - ISSN 1743-7555. - 14:(2018), pp. 48-48. [10.1111/ajco.13020]

Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma

Ascierto P
2018
2018
Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma / Ascierto, P.. - In: ASIA PACIFIC JOURNAL OF CLINICAL ONCOLOGY. - ISSN 1743-7555. - 14:(2018), pp. 48-48. [10.1111/ajco.13020]
1.5 Abstract in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1014202
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact